Sharp Financial Services LLC Buys 50 Shares of Eli Lilly and Company $LLY

Sharp Financial Services LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 431 shares of the company’s stock after buying an additional 50 shares during the period. Sharp Financial Services LLC’s holdings in Eli Lilly and Company were worth $336,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Mitchell Sinkler & Starr PA boosted its holdings in Eli Lilly and Company by 1.2% during the second quarter. Mitchell Sinkler & Starr PA now owns 2,431 shares of the company’s stock worth $1,895,000 after buying an additional 30 shares during the last quarter. Valley Brook Capital Group Inc. boosted its holdings in Eli Lilly and Company by 1.3% during the second quarter. Valley Brook Capital Group Inc. now owns 1,602 shares of the company’s stock worth $1,249,000 after buying an additional 20 shares during the last quarter. Orca Investment Management LLC bought a new position in Eli Lilly and Company during the second quarter worth about $1,448,000. Ackerman Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 5.8% during the second quarter. Ackerman Capital Advisors LLC now owns 272 shares of the company’s stock worth $212,000 after buying an additional 15 shares during the last quarter. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new position in Eli Lilly and Company during the second quarter worth about $40,217,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Guggenheim lifted their price objective on Eli Lilly and Company from $875.00 to $948.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $948.06.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 2.6%

NYSE LLY opened at $833.08 on Monday. The stock has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47. The stock’s 50 day moving average price is $742.42 and its two-hundred day moving average price is $765.55. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.